Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

CareDx is poised for growth due to strong revenue growth and expansion into new markets, and their recent resolution of a Medicare issue has increased investor confidence. While competition and challenges in introducing new products should be monitored, the company's strategic acquisitions and plans for future growth make them a promising investment.

Bears say

CareDx is expected to generate revenue growth in the coming quarters through increased volume and adoption of its testing services and products in the transplant market, primarily driven by its artificial intelligence-based AlloHeme product designed to monitor cancer relapse in post-transplant patients. However, there may be potential integration risks and challenges in adoption of these products by clinicians and healthcare administrators, as well as the need for continued education and awareness. The success and potential revenue impact of the recent Naveris acquisition is also uncertain. Overall, the outlook appears positive but with some potential challenges and uncertainties.

CareDx (CDNA) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 4 analysts, CareDx (CDNA) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.